Pexa-vec in Phase III Trials
Pexa-Vec is the most advanced product candidate from SillaJen’s proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform. The vaccinia virus backbone (Wyeth strain) of Pexa-Vec has been used safely in millions of people as part of a worldwide vaccination program to eradicate smallpox. Pexa-Vec was engineered to selectively infect and replicate in cancer cells by exploiting the genetic changes that frequently occur in cancer. [Read More]
Read More
